Articles tagged "Alloantibodies"

2018 American Transplant Congress
Prolonged Cold Ischemia Storage of Renal Allografts Shifts DSA Specificity and Enchances Glomerular Injury
V. Gorbacheva, R. Fan, W. Baldwin, A. Valujskikh.
Immunology, Cleveland Clinic, Cleveland, OH.
Prolonged cold ischemia storage (CIS) of donor organs is a major risk factor for acute and chronic graft injury. The goal of this study was…
2018 American Transplant Congress
The Complexity of HLA-DQ
D. Pinelli, A. Tambur.
Northwestern University, Chicago.
Historically, HLA-DQ antigens and antibodies (Ab) were difficult to classify due to the lack of serological typing reagents. However, with the advent of molecular typing…
2018 American Transplant Congress
Failure to Remove De Novo Donor-Specific HLA Antibodies is Influenced by Antibody Properties and Identifies Kidney Recipients with Late Antibody-Mediated Rejection Destined to Graft Loss
A. Nocera,¹ M. Cioni,¹ A. Tagliamacco,² S. Basso,³ A. Innocente,⁴ I. Fontana,⁵ A. Magnasco,¹ A. Trivelli,¹ A. Gurrado,³ M. Ramondetta,⁴ S. Boghen,³ L. Catenacci,³ E. Verrina,¹ G. Garibotto,² G. Ghiggeri,¹ M. Cardillo,⁴ F. Ginevri,¹ P. Comoli.³
¹Pediatric Nephrology Unit, IRCCS G. Gaslini, Genova, Italy; ²Clinical Nephrology Unit, University of Genova, Genova, Italy; ³Transplant Immunology and Pediatric Hematology/Oncology, IRCCS Policlinico S. Matteo, Pavia, Italy; ⁴Transplantation Immunology, Ospedale Maggiore Policlinico, Milano, Italy; ⁵Kidney Transplant Surgery Unit, Ospedale Policlinico San Martino, Genova, Italy.
Late antibody-mediated rejection (AMR) is the major cause of renal allograft loss. Current research is focusing on identifying a performant risk stratification in order to…
2018 American Transplant Congress
Tocilizumab Stabilizes Renal Function in Kidney Transplant Recipients with Chronic Active Antibody Mediated Rejection (CAAMR)
S. Patel, S. Mohan, H. Fernandez, I. Batal, L. Ratner, J. Crew.
Columbia University, New York.
INTRO: CAAMR after kidney transplantation (KTx) is associated with rates of allograft failure approaching 50% at 2 years from injury involving T cells, B cells,…
2018 American Transplant Congress
Diagnostic Usefulness of Medullary C4d Staining in Renal Allografts
J. Von Visger,¹ C. Von Visger, A. Satoskar,² T. Nadasdy,² J. Hemminger,² S. Brodsky.²
¹Medicine, The Ohio State University Wexner Medical Center, Columbus, OH; ²Pathology, The Ohio State University Wexner Medical Center, Columbus, OH.
Background: Detection of peritubular capillary (PTC) complement C4d on renal allograft biopsy is a histologic marker (along with serum anti-donor antibody, PTC inflammatory cells and…
2018 American Transplant Congress
The Impact of Duration on Dialysis on the Pre-Transplant Allosensitization According to Panel Reactive Antibody Levels
Y. Jung,¹ D. Kim,¹ J. Lee,¹ S. Song,² J. Lee,³ B. Kim,⁴ J. Lee,¹ S. Kim,¹ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea; ²Department of Surgery, College of Medicine, Ewha Women's University, Seoul, Republic of Korea; ³Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; ⁴Departments of Nephrology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Purpose : Presensitization to human leukocyte antigen(HLA) is one of the most important barriers to overcome in the field of renal transplantation. Due to the…
2018 American Transplant Congress
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
J. Choi,¹ O. Aubert,² S. Louie,¹ N. Ammerman,¹ A. Vo,¹ A. Peng,¹ E. Huang,¹ R. Najjar,¹ D. Puliyanda,¹ S. Sethi,¹ M. Haas,¹ K. Lim,¹ A. Loupy,² S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Paris Translational Center for Organ Transplantation, Paris, France.
Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…
2018 American Transplant Congress
The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis
S. Wan,^1,2 T. Ying,^1,2 K. Wyburn,^1,2 D. Roberts,^3,4 M. Wyld,^1,2 S. Chadban.^1,2
¹Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Sydney Medical School, University of Sydney, Sydney, Australia; ³Department of Renal Medicine, Canberra Hospital and Health Services, Canberra, Australia; ⁴Medical School, Australian National University, Canberra, Australia.
Introduction: Current treatment strategies for antibody-mediated rejection (AMR) in kidney transplantation are based on low quality data from a small number of controlled trials. Novel…
2018 American Transplant Congress
Complement Fixing Donor-Specific Antibodies Are Associated with Increased Risk of Chronic Lung Allograft Dysfunction after Lung Transplantation
C. Ensor,¹ C. Iasella,¹ M. Mangiola,¹ M. Marrari,¹ M. Morrell,¹ N. Shigemura,² J. DCunha,¹ J. McDyer,¹ A. Zeevi.¹
¹University of Pittsburgh, Pittsburgh, PA; ²Temple University, Philadelphia, PA.
Purpose: Survival among lung transplant recipients (LTRs) remains poor compared to other solid organs.The presence of donor-specific antibodies (DSA) directed against donor human leukocyte antigen…
2018 American Transplant Congress
Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
N. Bath, S. Parajuli, G. Leverson, M. Jorgenson, J. Fose, T. Ellis, D. Kaufman, A. Djamali, R. Redfield.
Surgery, University of Wisconsin, Madison, WI.
Introduction: Basiliximab, alemtuzumab, and thymoglobulin are the most commonly used induction agents in the US. While many centers use depleting antibody induction therapy in patients…